Novel farnesylthiosalicylate (FTS)-eluting composite structures

European Journal of Pharmaceutical Sciences

Volumn 37, Issue 3-4, 2009, Pages 351-362

  Kraitzer, Amir ^a   Kloog, Yoel ^a   Zilberman, Meital ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Degradation; Drug eluting fibers; Drug eluting stents; Farnesylthiosalicylate (FTS); Stent coatings

Indexed keywords

COPOLYMER; FARNESYLTHIOSALICYLATE; FARNESYLTHIOSALICYLIC ACID; MAXON; POLYGLACTIN; POLYMER; SALICYLIC ACID DERIVATIVE; SALIRASIB; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; DEGRADATION; DRUG COATING; DRUG ELUTING STENT; DRUG RELEASE; DRUG STABILITY; EMULSION; FREEZE DRYING; HOST; HYDROPHOBICITY; KINETICS; MORPHOLOGY; NONHUMAN; PRIORITY JOURNAL; SWELLING; WATER TRANSPORT;

ALGORITHMS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; DRUG STABILITY; DRUG-ELUTING STENTS; EMULSIONS; FARNESOL; INDICATORS AND REAGENTS; KINETICS; METALS; MICROSCOPY, ELECTRON, SCANNING; PACLITAXEL; POROSITY; SALICYLIC ACIDS; SOLUBILITY; TENSILE STRENGTH;

EID: 67349258532     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2009.03.004     Document Type: Article

References (28)

1. Breitenbach A., Mohr D., and Kissel T. Biodegradable semi-crystalline comb polyesters influence the microsphere production by means of a supercritical fluid extraction technique (ASES). J. Control Release 63 (2000) 53-68
2. Commandeur S., van Beusekom H.M., and van der Giessen W.J. Polymers, drug release, and drug-eluting stents. J. Interv. Cardiol. 19 (2006) 500-506
3. Creel C.J., Lovich M.A., and Edelman E.R. Arterial paclitaxel distribution and deposition. Circ. Res. 86 (2000) 879-884
4. Drachman D.E., Edelman E.R., Seifert P., Groothuis A.R., Bornstein D.A., Kamath K.R., Palasis M., Yang D., Nott S.H., and Rogers C. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J. Am. Coll. Cardiol. 36 (2000) 2325-2332
5. Feng S., and Huang G. Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers. J. Control Release 71 (2001) 53-69
6. Finkelstein A., McClean D., Kar S., Takizawa K., Varghese K., Baek N., Park K., Fishbein M.C., Makkar R., Litvack F., and Eigler N.L. Local drug delivery via a coronary stent with programmable release pharmacokinetics. Circulation 107 (2003) 777-784
7. Fonseca C., Simoes S., and Gaspar R. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J. Control Release 83 (2002) 273-286
8. George J., Sack J., Barshack I., Keren P., Goldberg I., Haklai R., Elad-Sfadia G., Kloog Y., and Keren G. Inhibition of intimal thickening in the rat carotid artery injury model by a nontoxic Ras inhibitor. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 363-368
9. Halkin A., and Stone G.W. Polymer-based paclitaxel-eluting stents in percutaneous coronary intervention: a review of the TAXUS trials. J. Interv. Cardiol. 17 (2004) 271-282
10. Heldman A.W., Cheng L., Jenkins G.M., Heller P.F., Kim D.W., Ware Jr. M., Nater C., Hruban R.H., Rezai B., Abella B.S., Bunge K.E., Kinsella J.L., Sollott S.J., Lakatta E.G., Brinker J.A., Hunter W.L., and Froehlich J.P. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 103 (2001) 2289-2295
11. Hofma S.H., van der Giessen W.J., van Dalen B.M., Lemos P.A., McFadden E.P., Sianos G., Ligthart J.M., van Essen D., de Feyter P.J., and Serruys P.W. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur. Heart J. 27 (2006) 166-170
12. Jackson J.K., Smith J., Letchford K., Babiuk K.A., Machan L., Signore P., Hunter W.L., Wang K., and Burt H.M. Characterization of perivascular poly(lactic-co-glycolic acid) films containing paclitaxel. Int. J. Pharm. 283 (2004) 97-109
13. Kloog Y., and Cox A.D. Prenyl-binding domains: potential targets for Ras inhibitors and anti-cancer drugs. Semin. Cancer Biol. 14 (2004) 253-261
14. Kraitzer A., Ofek L., Schreiber R., and Zilberman M. Long-term in vitro study of paclitaxel-eluting bioresorbable core/shell fiber structures. J. Control Release 126 (2008) 139-148
15. Lagerqvist B., James S.K., Stenestrand U., Lindback J., Nilsson T., and Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N. Engl. J. Med. 356 (2007) 1009-1019
16. Li Y., Fukuda N., Kunimoto S., Yokoyama S., Hagikura K., Kawano T., Takayama T., Honye J., Kobayashi N., Mugishima H., Saito S., and Serie K. Stent-based delivery of antisense oligodeoxynucleotides targeted to the PDGF A-chain decreases in-stent restenosis of the coronary artery. J. Cardiovasc. Pharmacol. 48 (2006) 184-190
17. Lu L., Peter S.J., Lyman M.D., Lai H.L., Leite S.M., Tamada J.A., Uyama S., Vacanti J.P., Langer R., and Mikos A.G. In vitro and in vivo degradation of porous poly(dl-lactic-co-glycolic acid) foams. Biomaterials 21 (2000) 1837-1845
18. Marom M., Haklai R., Ben-Baruch G., Marciano D., Egozi Y., and Kloog Y. Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid. J. Biol. Chem. 270 (1995) 22263-22270
19. Moreno R., and Macaya C. Stent-based delivered anti-proliferative drugs in the prevention of coronary stent restenosis. Curr. Med. Chem. Cardiovasc. Hematol. Agents 3 (2005) 221-229
20. Ranade S.V., Miller K.M., Richard R.E., Chan A.K., Allen M.J., and Helmus M.N. Physical characterization of controlled release of paclitaxel from the TAXUS express 2 drug-eluting stent. J. Biomed. Mater. Res. A 71 (2004) 625-634
21. Rao S.V., Shaw R.E., Brindis R.G., Klein L.W., Weintraub W.S., and Peterson E.D. On-versus off-label use of drug-eluting coronary stents in clinical practice (report from the American College of Cardiology National Cardiovascular Data Registry [NCDR]). Am. J. Cardiol. 97 (2006) 1478-1481
22. Rogers C.D. Optimal stent design for drug delivery. Rev. Cardiovasc. Med. 5 Suppl. 2 (2004) S9-S15
23. Serruys P.W., Sianos G., Abizaid A., Aoki J., den Heijer P., Bonnier H., Smits P., McClean D., Verheye S., Belardi J., Condado J., Pieper M., Gambone L., Bressers M., Symons J., Sousa E., and Litvack F. The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES). J. Am. Coll. Cardiol. 46 (2005) 253-260
24. Venkatraman S., and Boey F. Release profiles in drug-eluting stents: issues and uncertainties. J. Control Release 120 (2007) 149-160
25. Virmani R., Guagliumi G., Farb A., Musumeci G., Grieco N., Motta T., Mihalcsik L., Tespili M., Valsecchi O., and Kolodgie F.D. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?. Circulation 109 (2004) 701-705
26. Wang X., Venkatraman S.S., Boey F.Y., Loo J.S., and Tan L.P. Controlled release of sirolimus from a multilayered PLGA stent matrix. Biomaterials 27 (2006) 5588-5595
27. Westedt U., Wittmar M., Hellwig M., Hanefeld P., Greiner A., Schaper A.K., and Kissel T. Paclitaxel releasing films consisting of poly(vinyl alcohol)-graft-poly(lactide-co-glycolide) and their potential as biodegradable stent coatings. J. Control Release 111 (2006) 235-246
28. Wu L., and Ding J. In vitro degradation of three-dimensional porous poly(d,l-lactide-co-glycolide) scaffolds for tissue engineering. Biomaterials 25 (2004) 5821-5830